December 4, 2016 08:59 PM ESTUpdated December 7, 06:49 PM

Kite adds promising leukemia responses in small CAR-T studies, then fires the starting gun on its rolling submission

John Carroll

Editor & Founder

Kite Pharmaceuticals $KITE has lined up a fresh batch of positive efficacy data for its lead CAR-T for advanced cases of acute lymphoblastic leukemia at …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Kite adds promising leukemia responses in small CAR-T studies, then fires the starting gun on its rolling submission

John Carroll

Editor & Founder

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Bristol Myers CEO signals dealmaking will be a top priority in 2025

Drugmakers see a substantial, but manageable, hit to business from tariffs. But the worst may lie ahead

Roche CEO warns that tariffs could impact dealmaking

Versant's latest biotech focuses on inflammatory diseases

Caribou lays off 32% of staff, cuts lupus cell therapy program before first patient

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Kite adds promis­ing leukemia re­spons­es in small CAR-T stud­ies, then fires the start­ing gun on its rolling sub­mis­sion

Editor & Founder

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Kite adds promising leukemia responses in small CAR-T studies, then fires the starting gun on its rolling submission